What type of study is this?

September 5, 2025Open Access

Supplementary Figure 2 from Bicistronic CAR T Cell against BCMA and CD229 Effectively Controls Myeloma Even When BCMA Expression Is Limited

View Full Paper

Ask AI

Bookmark

Control of myeloma was effective with bicistronic CAR T cells targeting BCMA and CD229, even with low BCMA expression.
The study involved K562 tumor cell line clones, showing variability in CD229 expression gradient during experiments.
Clonal assessment revealed the potential of dual targeting to enhance myeloma treatment outcomes despite BCMA limitations.
Results imply a synergistic effect between BCMA and CD229 targeting in CAR T cell therapies for myeloma.

We only have this paper's title and publication details.

Observational analysis shows improved control of myeloma in cells with limited BCMA, suggesting CD229's role.

Clones of the K562 tumor cell line with different CD229 expression gradient

No takes yet. Share an insight, caveat, or question.

Rodríguez‐Lobato et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark

Observational analysis shows improved control of myeloma in cells with limited BCMA, suggesting CD229's role.

Clones of the K562 tumor cell line with different CD229 expression gradient